Targeting the PD-1 pathway in pediatric solid tumors and brain tumors

References

• WardEDeSantisCRobbinsAKohlerBJemalAChildhood and adolescent cancer statistics, 2014CA A Cancer J Clin201464283103
   PubMed Web of Science ®Google Scholar
• RobertsSSChouAJCheungNKImmunotherapy of childhood sarcomasFront Oncol2015518126301204
   PubMed Web of Science ®Google Scholar
• EyrichMRachorJSchreiberSCWolflMSchlegelPGDendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectivesFront Pediatr201311224400258
   PubMed Web of Science ®Google Scholar
• CroceMCorriasMVRigoVFerriniSNew immunotherapeutic strategies for the treatment of neuroblastomaImmunotherapy20157328530025804480
   PubMedGoogle Scholar
• YuALGilmanALOzkaynakMFAnti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastomaN Engl J Med2010363141324133420879881
   PubMed Web of Science ®Google Scholar
• GalonJAngellHKBedognettiDMarincolaFMThe continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signaturesImmunity2013391112623890060
   PubMed Web of Science ®Google Scholar
• DaudACurrent and emerging perspectives on immunotherapy for melanomaSemin Oncol201542Suppl 3S3S11
   PubMedGoogle Scholar
• SchmidingerMHejnaMZielinskiCCAldesleukin in advanced renal cell carcinomaExpert Rev Anticancer Ther20044695798015606326
   PubMedGoogle Scholar
• AmariaRNReubenACooperZAWargoJAUpdate on use of aldesleukin for treatment of high-risk metastatic melanomaImmunotargets Ther20154798927471714
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• MerchantMSWrightMBairdKPhase I clinical trial of ipilimumab in pediatric patients with advanced solid tumorsClin Cancer Res20162261364137026534966
   PubMed Web of Science ®Google Scholar
• RobertCSchachterJLongGVPembrolizumab versus ipilimumab in advanced melanomaN Engl J Med2015372262521253225891173
   PubMed Web of Science ®Google Scholar
• LarkinJChiarion-SileniVGonzalezRCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med20153731233426027431
   PubMed Web of Science ®Google Scholar
• BarberDLWherryEJMasopustDRestoring function in exhausted CD8 T cells during chronic viral infectionNature2006439707768268716382236
   PubMed Web of Science ®Google Scholar
• BoussiotisVAMolecular and biochemical aspects of the PD-1 checkpoint pathwayN Engl J Med2016375181767177827806234
   PubMed Web of Science ®Google Scholar
• Abdel-WahabNShahMSuarez-AlmazorMEAdverse events Associated with immune checkpoint blockade in patients with cancer: a systematic review of case reportsPLoS One2016117e016022127472273
   PubMed Web of Science ®Google Scholar
• ParishCRCancer immunotherapy: the past, the present and the futureImmunol Cell Biol200381210611312631233
   PubMed Web of Science ®Google Scholar
• GibneyGTWeinerLMAtkinsMBPredictive biomarkers for checkpoint inhibitor-based immunotherapyLancet Oncol20161712e542e55127924752
   PubMed Web of Science ®Google Scholar
• HutarewGPD-L1 testing, fit for routine evaluation? From a pathologist’s point of viewMemo20169420120628058063
   PubMedGoogle Scholar
• MotzerRJEscudierBMcDermottDFNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191803181326406148
   PubMed Web of Science ®Google Scholar
• SharmaPRetzMSiefker-RadtkeANivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialLancet Oncol2017 pii: S1470–S2045(17)30065–30067
   Web of Science ®Google Scholar
• BellmuntJde WitRVaughnDJPembrolizumab as second-line therapy for advanced urothelial carcinomaN Engl J Med20173761015102628212060
   PubMed Web of Science ®Google Scholar
• HiggsBWMorehouseCStreicherKRelationship of baseline tumoral IFNγ mRNA and PD-L1 protein expression to overall survival in durvalumab-treated NSCLC patientsJ Clin Oncol201634 Suppl; abstr 3036
   Google Scholar
• LeDTUramJNWangHPD-1 blockade in tumors with mismatch-repair deficiencyN Engl J Med2015372262509252026028255
   PubMed Web of Science ®Google Scholar
• WuXGiobbie-HurderALiaoXAngiopoietin-2 as a biomarker and target for immune checkpoint therapyCancer Immunol Res201751172828003187
   PubMedGoogle Scholar
• HintsalaEBonoPAnderssonSKivivuoriSMQuantification of plasma and bone marrow VEGF and angiopoietin-2 levels in pediatric malignanciesJ Pediatr Hematol Oncol201234750351022735882
   PubMed Web of Science ®Google Scholar
• MartinAMNirschlTRNirschlCJPaucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistanceProstate Cancer Prostatic Dis201518432533226260996
   PubMed Web of Science ®Google Scholar
• KorkolopoulouPKaklamanisLPezzellaFHarrisALGatterKCLoss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancerBr J Cancer19967321481538546899
   PubMed Web of Science ®Google Scholar
• SprangerSGajewskiTFA new paradigm for tumor immune escape: beta-catenin-driven immune exclusionJ Immunother Cancer201534326380088
   PubMed Web of Science ®Google Scholar
• HolmgaardRBZamarinDMunnDHWolchokJDAllisonJPIndoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4J Exp Med201321071389140223752227
   PubMed Web of Science ®Google Scholar
• O’DonnellJSLongGVScolyerRATengMWSmythMJResistance to PD1/PDL1 checkpoint inhibitionCancer Treat Rev201752718127951441
   PubMed Web of Science ®Google Scholar
• ChowdhuryFDunnSMitchellSMellowsTAshton-KeyMGrayJCPD-L1 and CD8+PD1+ lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapyOncoImmunology2015410e1029701
   Google Scholar
• KoiralaPRothMEGillJImmune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcomaSci Rep201663009327456063
   PubMed Web of Science ®Google Scholar
• LussierDMO’NeillLNievesLMEnhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactionsJ Immunother20153839610625751499
   PubMed Web of Science ®Google Scholar
• ShenJKCoteGMChoyEProgrammed cell death ligand 1 expression in osteosarcomaCancer Immunol Res20142769069824866169
   PubMed Web of Science ®Google Scholar
• KansaraMTengMWSmythMJThomasDMTranslational biology of osteosarcomaNat Rev Cancer2014141172273525319867
   PubMed Web of Science ®Google Scholar
• MeyersPAMuramyl tripeptide (mifamurtide) for the treatment of osteosarcomaExpert Rev Anticancer Ther2009981035104919671023
   PubMed Web of Science ®Google Scholar
• PaydasSBagirEKDeveciMAGonlusenGClinical and prognostic significance of PD-1 and PD-L1 expression in sarcomasMed Oncol20163389327421997
   PubMedGoogle Scholar
• KimCKimEKJungHPrognostic implications of PD-L1 expression in patients with soft tissue sarcomaBMC Cancer20161643427393385
   PubMedGoogle Scholar
• AokiTHinoMKohKLow frequency of programmed death ligand 1 expression in pediatric cancersPediatr Blood Cancer20166381461146427135656
   PubMed Web of Science ®Google Scholar
• DonderoAPastorinoFDella ChiesaMPD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillanceOncoimmunology201651e106457826942080
   PubMedGoogle Scholar
• MajznerRGMartinezDPawelBAssessment of PD-L1 expression and tumor associated immune cells in pediatric cancer tissuesJ Clin Oncol201634 Suppl; abstr 11542
   Google Scholar
• ZengJZhangXKChenHDZhongZHWuQLLinSXExpression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomasOncotarget2016788944895526771840
   PubMedGoogle Scholar
• Viana-PereiraMLeeAPopovSMicrosatellite instability in pediatric high grade glioma is associated with genomic profile and differential target gene inactivationPLoS One201165e2058821637783
   PubMedGoogle Scholar
• WimmerKRosenbaumTMessiaenLConnections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1Clin Genet Epub20161025
   Google Scholar
• BouffetELaroucheVCampbellBBImmune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiencyJ Clin Oncol201634192206221127001570
   PubMed Web of Science ®Google Scholar
• BlumenthalDTYalonMVainerGWPembrolizumab: first experience with recurrent primary central nervous system (CNS) tumorsJ Neurooncol2016129345346027377654
   PubMedGoogle Scholar
• BurgessMACrowleyJReinkeDKSARC 028: A phase II study of the anti-D1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomasJ Clin Oncol201533 suppl; abstr TPS10578
   PubMedGoogle Scholar
• McCaughanGJFulhamMJMaharAProgrammed cell death-1 blockade in recurrent disseminated Ewing sarcomaJ Hematol Oncol2016914827259563
   PubMedGoogle Scholar
• WeberJSPostowMLaoCDSchadendorfDManagement of adverse events following treatment with anti-programmed death-1 agentsOncologist201621101230124027401894
   PubMed Web of Science ®Google Scholar
• NishinoMImmune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatmentJ Immunother Cancer201643027330803
   PubMedGoogle Scholar
• ZhuXMcDowellMMNewmanWCMasonGEGreeneSTamberMSSevere cerebral edema following nivolumab treatment for pediatric glioblastoma: case reportJ Neurosurg Pediatr2016191527715484
   PubMedGoogle Scholar
• D’AngeloSPLarkinJSosmanJAEfficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysisJ Clin Oncol201735222623528056206
   PubMed Web of Science ®Google Scholar
• BracciLSchiavoniGSistiguABelardelliFImmune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancerCell Death Differ2014211152523787994
   PubMed Web of Science ®Google Scholar
• ChangCLHsuYTWuCCDose-dense chemotherapy improves mechanisms of antitumor immune responseCancer Res201373111912723108141
   PubMedGoogle Scholar
• KangJDemariaSFormentiSCurrent clinical trials testing the combination of immunotherapy with radiotherapyJ Immunother Cancer201645127660705
   PubMed Web of Science ®Google Scholar
• Hu-LieskovanSMokSHomet MorenoBImproved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanomaSci Transl Med20157279279ra241
   Web of Science ®Google Scholar
• KarakiSAnsonMTranTIs there still room for cancer vaccines at the era of checkpoint inhibitorsVaccines (Basel)20164437
   PubMedGoogle Scholar
• BaasPGaronEBHerbstRSRelationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab versus docetaxel for previously treated, PD-L1-positive NSCLCJ Clin Oncol201634 Suppl; abstr 9015
   Google Scholar
• BorghaeiHBrahmerJNivolumab in nonsquamous non-small-cell lung cancerN Engl J Med20163745493494
   PubMed Web of Science ®Google Scholar
• RittmeyerABarlesiFWaterkampDAtezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialLancet201738610066255265
   Google Scholar
• LongGVLarkinJAsciertoPAPD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): a pooled analysisESMO 2016 Congress in Copenhagen, Denmark2016 Suppl; Abstr 1112PD
   Google Scholar
• KeffordRRibasAHamidOClinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475J Clin Oncol201432 Suppl; abstr 3005
   Google Scholar
• SeiwertTYBurtnessBMehraRSafety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialLancet Oncol201617795696527247226
   PubMed Web of Science ®Google Scholar
• FehrenbacherLSpiraABallingerMAtezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLancet2016387100301837184626970723
   PubMed Web of Science ®Google Scholar
• RizviNAHellmannMDSnyderACancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerScience2015348623012412825765070
   PubMed Web of Science ®Google Scholar